Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Sarah Griffiths practices corporate and securities law, with an emphasis on international and domestic capital-raising transactions. Her practice predominantly consists of capital markets transactions, including initial public offerings and follow-on equity offerings, involving issuers in the life sciences and financial services industries. She also regularly advises clients on corporate governance issues, mergers and acquisitions and other general corporate matters.

  • Seconded to the Corporate Governance and Securities group in the legal department of Bristol-Myers Squibb Company, focusing primarily on Securities Exchange Act reporting, corporate governance and federal securities law compliance (2015-2016).
  • Represented the underwriters in the $76.8 million initial public offering of common stock by a biopharmaceutical company focused on the discovery, development and commercialization of anti-infectives for treatment of diseases inadequately addressed by existing drugs.
  • Represented the underwriters in a $74 million follow-on public offering of common stock by a biopharmaceutical company focused on the treatment of hereditary angioedema.
  • Represented European telecommunications company Altice S.A. in a $9.1 billion transaction to acquire a controlling stake in Suddenlink, the seventh largest cable operator in the U.S.
  • Represented AstraZeneca in its acquisition of Bristol-Myers Squibb's interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion and up to $1.4 billion in regulatory, launch and sales-related payments.
  • Represented the underwriters in an offering of $500 million of investment-grade notes by a leading manufacturer and marketer of consumer and professional products.
  • Represented the underwriters in the $50 million initial public offering of Parnell Pharmaceutical Holdings Ltd, an Australian-domiciled pharmaceutical company developing and marketing products for companion animals and livestock.
  • Represented Lombard Medical, Inc., a UK-based medical device company focused on endovascular stent-grafts for the repair of aortic aneurysms, in its $55 million US IPO of ordinary shares.
  • OrbiMed Advisors in secured debt and equity investments in biotechnology, pharmaceutical and medical device companies.

Pro Bono

  • Alliance for the Arts, Inc., an arts education not-for-profit in connection with its corporate dissolution and the transfer of its intellectual property and technology assets.

Memberships and Affiliations

  • New York City Bar Association
  • New York County Lawyers’ Association